Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valensa Receives FDA & FSA Notifications for Zanthin - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Valensa Receives FDA & FSA Notifications for Zanthin

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Valensa International, (formerly U. S. Nutra), Eustis, FL, has indicated that a New Dietary Ingredient (NDI) notification to sell its Zanthin brand natural astaxanthin dietary supplement, has been reviewed without objection by the FDA. The company may now offer the product for sale and use in the U.S. as a human dietary supplement ingredient. This news follows Zanthin’s recent approval, under Regulation (EC) No. 258/97, from the U.K. Food Standards Agency (FSA), which recognized Zanthin as a non-novel dietary supplement, allowing it to be marketed at a maximum dose of 4 mg daily in the 25 member countries of the European Union.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters